TRILOGY Risk Models
Risk Models built on the TRILOGY ACS population

Risk Models


Bleeding

Spontaneous Myocardial Infarction

About


TRILOGY ACS was a double-blind, randomized trial, in a primary analysis involving 7243 patients under the age of 75 years receiving aspirin, evaluated up to 30 months of treatment with prasugrel (10 mg daily) versus clopidogrel (75 mg daily).

As a secondary analysis, several prediction models were built to help identify the risk of time-to first outcome in a medically managed ACS population. Please don't use these prediction models in any other population.